Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
University of Chicago
Study ID
NCT06499857
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.
  • Placebo — DRUG
    3ml pen-injector containing placebo solution for subcutaneous use.

Study Details

The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.

Key Dates

Start date
Apr 14, 2025
Status verified
Nov 2025
Primary completion
Dec 31, 2027
Completion
Jun 30, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Semaglutide
    Participants will have a 2 in 3 chance of receiving semaglutide (2.4 mg).
  • Placebo Comparator: Placebo
    Participants will have a 1 in 3 chance of receiving placebo.

Primary Outcome Measure

Time to first AF event detected by routine outpatient monitoring [ Time Frame: Baseline to Week 68 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
The University of Arizona College of Medicine- PhoenixPhoenixArizona85004
Roderick Tung, MD
[email protected]
602-521-3090
University of ChicagoChicagoIllinois60637
Silvana Pannain, MD
[email protected]
773-702-3275
Andrew Beaser, MD
[email protected]
773-702-9324

Find similar trials in Phoenix, AZ

By condition
Atrial fibrillation
By specialty
CardiologyHeart disease
By research site
The University of Arizona College of Medicine- Phoenix· Phoenix, AZUniversity of Chicago· Chicago, IL

Related Studies